The Évry ecosystem commits to the Biodrugs Major Challenge
On 3 February 2022, the French Government's Biodrugs Major Challenge action (a part of France 2030), with its budget of €13 million, retained eight novel technological projects for the production of innovative bio, gene or cell therapies aimed at rare or common diseases. The competencies of four Genopole entities, the laboratories ART-TG, CiTHERA and I-Stem and the company Yposkesi, will be called upon for three of the laureate projects:
- ASMA (Acoustic solutions for manufacturing advanced therapies) combines technologies to improve the key steps of gene material transfer and thus production yield in gene therapies.
- STELLAR (Stem cell differentiation evaluation on line–light holographic analysis recording) aims to be a continuous and non-destructive quality control system for cell therapies.
- SOFTCELL is taking inspiration from phytoplankton culturing to develop a bioreactor for the high-volume production of human stem cells.